Abbott Laboratories (ABT)
| Market Cap | 237.07B |
| Revenue (ttm) | 42.34B |
| Net Income (ttm) | 13.45B |
| Shares Out | 1.74B |
| EPS (ttm) | 7.70 |
| PE Ratio | 17.69 |
| Forward PE | 25.83 |
| Dividend | $2.36 (1.73%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | 5,337,139 |
| Open | 135.54 |
| Previous Close | 136.01 |
| Day's Range | 134.81 - 137.08 |
| 52-Week Range | 99.71 - 141.23 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 140.44 (+3.07%) |
| Earnings Date | Jul 17, 2025 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for ABT stock is "Buy." The 12-month stock price target is $140.44, which is an increase of 3.07% from the latest price.
News
Abbott Labs: Proactive, Adaptive, Solid
Abbott's proactive leadership and diversified business model help it navigate macro challenges and market volatility effectively. Strong Q1 performance in Nutrition, Medical Devices, and Vascular segm...
Abbott Laboratories: FreeStyle Libre CGMs And EPD Business Driving Positive Momentum
Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before, potentially resulting in a 15% CAGR in FreeStyle Libre sales by 2028. With ...
Best Dividend Aristocrats For July 2025
Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising pa...
Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens.
New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier
Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reporte...
Abbott Declares 406th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.
The Highest-Quality Dividend Contenders By Quality Scores
The article presents the highest-quality Dividend Contenders, companies listed on U.S. exchanges with higher annual dividend payouts for 10-24 consecutive years. I use a quality scoring system with si...
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.
Best Dividend Aristocrats For June 2025
Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 20...
Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery
The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne offers a n...
Abbott Laboratories: Why Wall Street's Skepticism Misses The Real Story
Abbott remains a Buy at $131 for its steady cash flow, strong fundamentals, and long-term healthcare growth, despite short-term revenue concerns. Wall Street underestimates ABT's operational disciplin...
Abbott India's quarterly profit climbs 28% on strong demand
Drugmaker Abbott India reported a 28% rise in fourth-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.
Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is link...
Abbott Labs CEO on federal health care spending, investing in healthy people and weight loss drugs
Robert Ford, Abbott Labs CEO, joins 'Power Lunch' to discuss government spending on health care and technological investments.
US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease
A federal judge on Friday said she will allow expert testimony that formula made by Abbott Laboratories and Reckitt Benckiser subsidiary Mead Johnson for premature babies can cause a fatal intestinal ...
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races
The test, run on Abbott's portable i-STAT ® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concuss...
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...
Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information
Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data f...
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also b...
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE ...
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising...
Abbott Labs' Rally Is Well Deserved - Fade The Rally For Now
ABT continues to offer a compelling high-growth investment thesis, driven by the GLP-1 tailwinds on its Continuous Glucose Monitoring and adult nutrition offerings. This is significantly aided by the ...
These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings
Abbott Laboratories ABT reported better-than-expected first-quarter adjusted EPS results on Wednesday.